Journals By Industry - Central Nervous System Drugs

Keppra was previously approved in the US as adjunctive therapy for partial onset seizures in adults and children four years of age and older with epilepsy. The approval was based on data from...

Tokyo, Jan 19, 2012 - (JCN) - Otsuka Pharmaceutical Co. Ltd, a wholly owned direct subsidiary of Otsuka Holdings Co. Ltd, and UCB will be focusing their collaboration on the therapeutic area of...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/dc23a6/emerging_technolog) has announced the addition of the "Emerging Technologies: Stem Cells" report to their offering. Stem cell therapies will play an increasingly important role in the underserved field...

Tokyo, Jan 18, 2012 - (JCN Newswire) - Eisai Co. Ltd announced today that it received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) on January 18, 2012 to market Lunesta...

BRIDGEWATER, N.J. -- NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced that, as previously disclosed, it is continuing to explore various...

ROCKVILLE, Md. -- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/57b733/market_and_product) has announced the addition of the "Market and Product Forecasts: Depression - Agomelatine failure creates US market opportunity" report to their offering. New product launches across the...

XenoPort to Receive $10 Million Milestone Payment TOKYO & SANTA CLARA, Calif. -- Astellas Pharma Inc. (Tokyo:4503) and XenoPort, Inc. (NASDAQ:XNPT) announced today that Regnite([R] ) (gabapentin enacarbil) has received marketing approval in...

According to Pfizer and Medivation, Dimebon (latrepirdine) failed to meet either of its co-primary endpoints in the Phase III trial. Over the course of 12 months, no statistically significant improvements were noted on...

* Closed approximately $630.0 million in Commitments in 2011, up 20% Year-over-Year * Closed approximately $165.0 million in Commitments to new and existing portfolio companies in the Fourth Quarter * Entered into an...

ROCKVILLE, Md. -- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2012. "Rexahn...

Dimebon Did Not Meet Primary Efficacy Endpoints SAN FRANCISCO & NEW YORK -- Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3...

BERLIN -- JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy...

EMERYVILLE, Calif. -- KineMed, Inc. (www.kinemed.com) announced today that co-founders Marc Hellerstein M.D., Ph.D., Chairman of the Scientific Advisory Board of KineMed and David Fineman, KineMed's CEO, will present at the 2012 Personalized...

Research to Provide Foundation for Use of Biocompatible Hydrogel Therapies Beyond Spinal Cord Injury Treatment CAMBRIDGE, Mass. & DANVILLE, Pa. -- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for...

EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd.,for marketing in South Korea. Antares will receive undisclosed...

NEW YORK -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012. Reported earnings per...

NEW YORK & PETACH TIKVAH -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that the data from the...

San Diego-based Arena Pharmaceuticals Inc. said that the Food and Drug Administration has accepted its resubmitted New Drug Application for its investigational obesity pill lorcaserin, with approval decision set for June 27. The...